Europe Hematuria Treatment Market Share and Forecast by 2028

Europe Hematuria Treatment Market Forecast to 2028 - COVID-19 Impact and Regional Analysis By Treatment (Drugs, Therapies, and Others), Indication (Urinary Tract Infections, Kidney Stones, Urethritis, Blood Cancer, Bladder Stones, Prostate Cancer, Cystitis, Trauma, Vigorous Exercise, Polycystic Kidney Disease, Endometriosis, and Menstruation), Type (Macroscopic Hematuria, Microscopic Hematuria, Idiopathic Hematuria, and Jogger’s Hematuria), End User (Hospitals, Clinics, and Ambulatory Surgical Centers, and Others)

Historic Data: 2019-2020 | Base Year: 2021 | Forecast Period: 2022-2028

Status : Published
Report Code : TIPRE00026250

Category : Life Sciences
No. of Pages : 177

Available Report Formats :

Europe Hematuria Treatment Market Share and Forecast by 2028

Report Date: Dec 2021 | Report Code: TIPRE00026250 Email: sales@theinsightpartners.com

Analysis Strategic Insights Market Drivers Report Scope Recent Developments FAQs

The Europe hematuria treatment market is expected to reach US$ 313.8 million by 2028 from US$ 270.5 million in 2021. The market is estimated to grow at a CAGR of 2.1% from 2021–2028.

Healthcare expenditure has considerably increased due to the rising prevalence of chronic indications. The governments of various economies are investing substantially in improving the healthcare infrastructure. Moreover, patients in developed economies are becoming aware of the possible treatments and availability of reimbursement for the hematuria treatment. Hematuria is among the initial indications of chronic diseases such as blood cancer, bladder cancer, and kidney cancer. These diseases are covered under various health insurance policies that help the easy treatment of the patients and reduce the financial burden for healthcare. Thus, improving healthcare expenditure and awareness among the patients about the treatment is driving the hematuria treatment market.

A variety of patients have reported progressive acute kidney injury (AKI) at admission and during hospitalization and mild proteinuria symptoms for hematuria, which are associated with adverse clinical outcomes in inpatients with COVID 19. Proteinuria and hematuria are reported to have an even higher prevalence in COVID-19 than AKI. Retrospective studies in China have reported that proteinuria and hematuria are associated with COVID-19 and with higher mortality. In addition, according to the European Kidney Association (ERACODA) COVID19 database established in March 2020, approximately 25% of kidney transplant patients are diagnosed with coronavirus. Therefore, an increase in COVID-positive patients is expected to be more likely to be treated for kidney disease.

With the new features and technologies, vendors can attract new customers and expand their footprints in emerging markets. This factor is likely to drive the hematuria treatment market. The Europe hematuria treatment market is expected to grow at a good CAGR during the forecast period.

Europe Hematuria Treatment Market Revenue and Forecast to 2028 (US$ Million)

Europe Hematuria Treatment Market Segmentation

By Treatment

Drugs
Therapies
Others

By Indication

Urinary Tract Infections
Kidney Stones
Urethritis
Blood Cancer
Bladder Stones
Prostate Cancer
Cystitis
Trauma
Vigorous Exercise
Polycystic Kidney Disease
Endometriosis
Menstruation

By Type

Macroscopic Hematuria
Microscopic Hematuria
Idiopathic Hematuria
Jogger’s Hematuria

By End User

Hospitals
Clinics
Ambulatory Surgical Centers (ASC's)
Others

By Country

Europe
- Germany
- UK
- France
- Spain
- Italy
- Rest of Europe

Companies Mentioned

AstraZeneca
Bristol-Myers Squibb Company
F. HOFFMANN-LA ROCHE LTD.
GlaxoSmithKline plc.
Janssen Pharmaceuticals
Merck & Co., Inc.
Novartis AG
Pfizer Inc.
Sun Pharmaceutical Industries Ltd
Boehringer Ingelheim International GmbH

Europe Hematuria Treatment Report Scope

Report Attribute	Details
Market size in 2021	US$ 270.5 Million
Market Size by 2028	US$ 313.8 Million
CAGR (2021 - 2028)	2.1%
Historical Data	2019-2020
Forecast period	2022-2028
Segments Covered	By Treatment Drugs Therapies By Indication Urinary Tract Infections Kidney Stones Urethritis Blood Cancer Bladder Stones Prostate Cancer Cystitis Trauma Vigorous Exercise Polycystic Kidney Disease Endometriosis Menstruation By Type Macroscopic Hematuria Microscopic Hematuria Idiopathic Hematuria Jogger's Hematuria By End User Hospitals Clinics Ambulatory Surgical Centers
Regions and Countries Covered	Europe UK Germany France Russia Italy Rest of Europe
Market leaders and key company profiles	AstraZeneca Bristol-Myers Squibb Company F. HOFFMANN-LA ROCHE LTD. GlaxoSmithKline plc. Janssen Pharmaceuticals Merck & Co., Inc. Novartis AG Pfizer Inc. Sun Pharmaceutical Industries Ltd Boehringer Ingelheim International GmbH

Research Manager

Mrinal Kerhalkar

Manager,
Market Research & Consulting

Mrinal is a seasoned research analyst with over 8 years of experience in Life Sciences Market Intelligence and Consulting. With a strategic mindset and unwavering commitment to excellence, she has built deep expertise in pharmaceutical forecasting, market opportunity assessment, and developing industry benchmarks. Her work is anchored in delivering actionable insights that empower clients to make informed strategic decisions.

Mrinal’s core strength lies in translating complex quantitative datasets into meaningful business intelligence. Her analytical acumen is instrumental in shaping go-to-market (GTM) strategies and uncovering growth opportunities across the pharmaceutical and medical device sectors. As a trusted consultant, she consistently focuses on streamlining workflow processes and establishing best practices, thereby driving innovation and operational efficiency for her clients.

What are the Europe Hematuria Treatment Market report deliverables?

Historical Analysis (2 Years), Base Year, Forecast (7 Years) with CAGR
PEST and SWOT Analysis
Market Size Value / Volume - Regional, Country
Industry and Competitive Landscape
Excel Dataset

Recent Reports

Testimonials

The Insight Partners' SCADA System Market report is comprehensive, with valuable insights on current trends and future forecasts. The team was highly professional, responsive, and supportive throughout. We are very satisfied and highly recommend their services.

RAN KEDEM Partner, Reali Technologies LTDs

I requested a report on a very specific software market and the team produced the report in a few days. The information was very relevant and well presented. I then requested some changes and additions to the report. The team was again very responsive and I got the final report in less than a week.

JEAN-HERVE JENN Chairman, Future Analytica

We worked with The Insight Partners for an important market study and forecast. They gave us clear insights into opportunities and risks, which helped shape our plans. Their research was easy to use and based on solid data. It helped us make smart, confident decisions. We highly recommend them.

PIYUSH NAGPAL Sr. Vice President, High Beam Global

The Insight Partners delivered insightful, well-structured market research with strong domain expertise. Their team was professional and responsive throughout. The user-friendly website made accessing industry reports seamless. We highly recommend them for reliable, high-quality research services

YUKIHIKO ADACHI CEO, Deep Blue, LLC.

This is the first time I have purchased a market report from The Insight Partners.While I was unsure at first, I visited their web site and felt more comfortable to take the risk and purchase a market report.I am completely satisfied with the quality of the report and customer service. I had several questions and comments with the initial report, but after a couple of dialogs over email with their analyst I believe I have a report that I can use as input to our strategic planning process.Thank you so much for taking the extra time and making this a positive experience.I will definitely recommend your service to others and you will be my first call when we need further market data.

JOHN SUZUKI President and Chief Executive Officer, Board Director, BK Technologies

I wish to appreciate your support and the professionalism you displayed in the course of attending to my request for information regarding to infectious disease IVD market in Nigeria. I appreciate your patience, your guidance, and the fact that you were willing to offer a discount, which eventually made it possible for us to close a deal. I look forward to engaging The Insight Partners in the future, all thanks to the impression you have created in me as a result of this first encounter.

DR CHIJIOKE ONYIA MANAGING DIRECTOR, PineCrest Healthcare Ltd.

Reason to Buy